Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion.
about
New treatment options for late Na current, arrhythmias, and diastolic dysfunctionRole of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death.Ranolazine recruits muscle microvasculature and enhances insulin action in rats.Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazineMechanisms Underlying the Emergence of Post-acidosis Arrhythmia at the Tissue Level: A Theoretical Study.Emerging clinical role of ranolazine in the management of angina.Efficacy and safety of ranolazine in patients with chronic stable angina.Intracoronary pyruvate in cardiogenic shock as an adjunctive therapy to catecholamines and intra-aortic balloon pump shows beneficial effects on hemodynamics.Electrophysiologic basis for the antiarrhythmic actions of ranolazine.Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure.Selective inhibition of late sodium current suppresses ventricular tachycardia and fibrillation in intact rat hearts.Ranolazine: an anti-anginal drug with further therapeutic potential.The utility of the small rodent electrocardiogram in toxicology.Ischemic ventricular arrhythmias: experimental models and their clinical relevanceRanolazine: an antianginal drug with antiarrhythmic properties.Stable angina pectoris: antianginal therapies and future directions.A focus on antiarrhythmic properties of ranolazine.Late sodium current inhibition in acquired and inherited ventricular (dys)function and arrhythmias.Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.Ranolazine: clinical applications and therapeutic basis.New antiarrhythmic targets to control intracellular calcium handling.Ranolazine treatment for myocardial infarction? Effects on the development of necrosis, left ventricular function and arrhythmias in experimental models.Rat Models of Ventricular Fibrillation Following Acute Myocardial Infarction.Ranolazine: safe and effective in a patient with hypertensive cardiomyopathy and multiple episodes of electrical storm.Voltage-gated channel mechanosensitivity: fact or friction?Dynamics and sensitivity analysis of high-frequency conduction block.Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery.Absence of actions of commonly used Chinese herbal medicines and electroacupuncture on myocardial infarct size.Ranolazine improves diastolic function in spontaneously hypertensive rats.First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model.Protective effects of ranolazine and propranolol, alone or combined, on the structural and functional alterations of cardiomyocyte mitochondria in a pig model of ischemia/reperfusion.Impact of ranolazine on ventricular arrhythmias - A systematic review.
P2860
Q27012532-068B84F9-B29E-4850-9A44-CB029BB50BE9Q27339434-F39CD41C-0F45-4C35-B5D3-2F228D847F98Q30456763-79FA7BE1-23A6-4AE1-803F-E43CC69C427AQ30622882-80872F18-75BB-4AA0-9AA9-FDC13BF31911Q30843252-4AD7CDC8-9210-46A1-91C5-F27B626CCE8FQ34235939-05D1A0AE-8622-472B-8528-C7E612704FD3Q34383219-A85ED84C-F5AC-418D-B553-ECAA16E60BF8Q34820186-4FC9215F-B1A3-4106-8442-19663D8CCD6EQ35091243-6FD1781B-D7A6-4385-8FE0-4A88732B3819Q36841418-AAF8A6A8-A4E6-4162-8540-3D2C559D3928Q37658443-D9F881CD-2E34-45D4-B5F2-3B17BB6A913AQ37707393-1A0B4AF2-955F-4B7F-8F8B-0B3540563F60Q37833375-F91783A0-9969-48F0-A05A-BE097F5BB164Q37899322-0F9F26FD-7D1A-405E-897E-FCF76E02629FQ37910205-4E381FBC-54C0-475E-A926-998CE0E1F2B8Q37924086-B6FBA037-A3D5-4106-A48A-A47175013A0AQ38001669-9561C120-C46F-478C-9315-D3F08DF417EFQ38071920-ABB92D7F-BAE1-4F59-A892-0F00C4F6CCDEQ38074900-DF4738CA-F188-4BD3-9F12-47C2AA05693CQ38075519-0ACB0A6B-3F69-40C1-9453-E733C5E2A8B4Q38204723-7C1C9616-F2C4-4C4D-9521-155E54DD1392Q38238926-CE59378C-925A-44C7-AB7E-94AAE8B4B064Q39222500-E4317C20-E27B-4C68-9BEB-E2B73C05E5FAQ40981113-D794D39A-CE52-4AF1-AD8D-8947554BABB9Q42215065-41188DA2-710F-4DC2-8CE1-F22814A3E074Q42272725-B07920F3-0287-4005-B891-423DCE4BFA02Q44627954-B8387B70-7BD2-4B0E-AAD9-166AAA8FDBA9Q47312625-54FB3939-E29A-4E0C-A08C-5C332E47B708Q47919972-D5357ACF-0F9B-41EB-BE7F-AE4E9F6E2479Q48299852-7E8D9770-4B0D-49A1-8ED7-F0714EEF626EQ51052441-0472B985-995E-4A53-83EF-834391464F39Q52587219-05B47657-56F1-45C3-97ED-20FC3969A834
P2860
Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Ranolazine, an antianginal age ...... emia and ischemia-reperfusion.
@en
Ranolazine, an antianginal age ...... emia and ischemia-reperfusion.
@nl
type
label
Ranolazine, an antianginal age ...... emia and ischemia-reperfusion.
@en
Ranolazine, an antianginal age ...... emia and ischemia-reperfusion.
@nl
prefLabel
Ranolazine, an antianginal age ...... emia and ischemia-reperfusion.
@en
Ranolazine, an antianginal age ...... emia and ischemia-reperfusion.
@nl
P2093
P2860
P1476
Ranolazine, an antianginal age ...... emia and ischemia-reperfusion.
@en
P2093
Anil Bhandari
Arvinder K Dhalla
John C Shryock
Luiz Belardinelli
Robert A Kloner
Wei-Qun Wang
P2860
P304
P356
10.1152/AJPHEART.00173.2009
P577
2009-09-18T00:00:00Z